Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Serina Therapeutics (SER) Short-Term Debt issuances (2021 - 2024)

Serina Therapeutics' Short-Term Debt issuances history spans 4 years, with the latest figure at $110000.0 for Q4 2024.

  • For Q4 2024, Short-Term Debt issuances changed N/A year-over-year to $110000.0; the TTM value through Sep 2025 reached $110000.0, down 96.25%, while the annual FY2024 figure was $3.0 million, N/A changed from the prior year.
  • Short-Term Debt issuances for Q4 2024 was $110000.0 at Serina Therapeutics, up from $8000.0 in the prior quarter.
  • Across five years, Short-Term Debt issuances topped out at $11.5 million in Q1 2023 and bottomed at -$13.5 million in Q3 2023.
  • The 4-year median for Short-Term Debt issuances is $1.5 million (2021), against an average of $964846.2.
  • The largest YoY upside for Short-Term Debt issuances was 666.67% in 2023 against a maximum downside of 1450.0% in 2023.
  • A 4-year view of Short-Term Debt issuances shows it stood at $1.5 million in 2021, then changed by 0.0% to $1.5 million in 2022, then plummeted by 1000.0% to -$13.5 million in 2023, then soared by 100.81% to $110000.0 in 2024.
  • Per Business Quant, the three most recent readings for SER's Short-Term Debt issuances are $110000.0 (Q4 2024), $8000.0 (Q3 2024), and $525000.0 (Q2 2024).